Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events

Table 1 Sociodemographic and clinical characteristics of patients receiving voriconazole TDM between 2007-2009

Variable	Patients with voriconazole drug monitoring [n, (%)]
Number of patients	108
Median Age (IQR)	53 (38–64)
Sex, % male	59 (54.6%)
Underlying condition
Hematopoietic stem cell transplant	47 (43.5%)
Hematologic malignancy without a stem cell transplant	37 (34.3%)
Solid organ transplantation	10 (9.3%)
Other condition	9 (8.3%)
None	3 (2.8%)
Reason for voriconazole treatment*
Invasive pulmonary aspergillosis	83 (76.8%)
Invasive sinus or CNS aspergillosis	5 (4.6%)
Invasive candidal infection	9 (8.3%)
Other invasive fungal infection^δ	13 (12.0%)
Febrile neutropenia	9 (8.3%)
Diagnosis of infection
Proven or probable invasive fungal disease	46 (42.5%)
Possible invasive fungal disease	43 (39.8%)
Voriconazole initial drug level
Subtherapeutic (<1.0 mg/L)	32 (29.6%)
Therapeutic (1.0-5.5 mg/L)	64 (59.2%)
Supratherapeutic (>5.5 mg/L)	12 (11.1%)

*Sixteen patients received voriconazole therapy for more than one indication.
^δ Other fungal organisms included Fusarium (n = 2), Absidia (n = 1), Alternaria (n = 1), Saccharomyces (n = 1), Scedosporium (n = 1), Ascomyctes (n = 1), Rhizopus (n = 1), Pseudoallescheria (n = 1), and Paecilomyces (n = 1).

ISSN: 1471-2334